SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549-1004
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
June 14, 2004
Date of Report (Date of Earliest Event Reported)
Dynatronics Corporation
(Exact name of registrant as specified in its charter)
UTAH 0-12697 87-0398434
(State or other jurisdiction (I.R.S. Employer
of incorporation) (Commission File Number) Identification No.)
7030 Park Centre Dr., Salt Lake City, UT 84121
(Address of principal executive offices) (Zip code)
(801) 568-7000 (Registrant's telephone number,
including area code)
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
99.1 Press Release issued by Dynatronics Corporation on June 14, 2004.
Item 9. REGULATION FD DISCLOSURE
On June 14, 2004, Dynatronics Corporation issued a press release announcing that
the U.S. Food and Drug Administration had given marketing clearance for the
company's new Solaris D890 low-power laser probe for the treatment of muscle and
joint pain as well as pain and stiffness associated with arthritis. The press
release is attached to this Current Report on Form 8-K as Exhibit 99.1.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
DYNATRONICS CORP.
DATE: June 14, 2004 By: /s/ Kelvyn H. Cullimore, Jr.
--------------------------------
Name: Kelvyn H. Cullimore, Jr.
Title: President
3